Europe-Wide study to settle debate on surgery for spread gut tumors
NCT ID NCT06787014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at people with small intestinal neuroendocrine tumors that have spread and cannot be cured. It compares those who had surgery to remove the main tumor plus other treatments against those who had only other treatments. The goal is to see if surgery helps patients live longer and avoid future bowel blockages. The study will review medical records from across Europe to provide clearer guidance for doctors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The investigators will include all patients with siNET and non-curative metastatic disease between 01.01.2005 and 31.12.2021.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- All patients with siNET and non-curative metastatic disease between 01.01.2005 and 31.12.2021 will be included. Exclusion Criteria: \- All patients with siNET G3, resectable metastatic disease and/or non-resectable primary tumor at initial diagnosis will be excluded. Furthermore, symptomatic patients (small intestinal obstruction, bleeding) or when imaging suggests that obstruction will probably occur (bowel dilatation, mesenteric fibrosis) at initial diagnosis will be excluded. Patients with diarrhea, flushing, or abdominal pain will not be excluded. Patients with a documented rejection for a further use of their data for scientific purposes will also be excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bowel obstruction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UHI Berne
RECRUITINGBern, 3010, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsed radiation extend life in metastatic cervical cancer?
- A sharper eye for cancer: new PET tracer targets hidden tumors
- Can a new tracer reveal hidden tumors and metastases?
- Can a new imaging tracer light up hidden tumors?
- Can a new imaging tracer reveal hidden tumors?
- Can a targeted drug tame neuroendocrine tumors in everyday practice?